Esperion Therapeutics (ESPR) Interest Coverage Ratio Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Interest Coverage Ratio Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -14.04% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -63.16% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -58.34% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 97.17% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -87.09% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -14.91% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 70.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.77% |
| Dec 31, 2025 | 2,200.52% |
| Sep 30, 2025 | 57.50% |
| Jun 30, 2025 | 84.29% |
| Mar 31, 2025 | -122.07% |
| Dec 31, 2024 | 93.63% |
| Sep 30, 2024 | 42.13% |
| Jun 30, 2024 | 107.37% |
| Mar 31, 2024 | 252.53% |
| Dec 31, 2023 | 5.16% |
| Sep 30, 2023 | 37.57% |
| Jun 30, 2023 | 30.57% |
| Mar 31, 2023 | -10.51% |
| Dec 31, 2022 | 28.37% |
| Sep 30, 2022 | 27.97% |
| Jun 30, 2022 | -25.76% |
| Mar 31, 2022 | 70.01% |
| Dec 31, 2021 | 61.29% |
| Sep 30, 2021 | 75.02% |
| Jun 30, 2021 | -110.49% |